Scarica l'app Stockscreener
1.81
4.23%
-0.08
Dopo l'orario di chiusura:
1.80
-0.01
-0.55%
Precedente Chiudi:
$1.89
Aprire:
$1.96
Volume 24 ore:
952.90K
Relative Volume:
1.71
Capitalizzazione di mercato:
$56.46M
Reddito:
$1.05M
Utile/perdita netta:
$-48.82M
Rapporto P/E:
-0.9891
EPS:
-1.83
Flusso di cassa netto:
$-47.49M
1 W Prestazione:
+16.77%
1M Prestazione:
+64.55%
6M Prestazione:
+0.56%
1 anno Prestazione:
-76.88%
Intervallo 1D:
$1.76
$1.98
Intervallo di 1 settimana:
$1.40
$2.41
Portata 52W:
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Nome
Actinium Pharmaceuticals Inc
Settore
Industria
Telefono
646-767-3870
Indirizzo
275 Madison Avenue, 7th Floor, New York, NY
Confronta ATNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.81 | 56.46M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Iniziato | B. Riley Securities | Buy |
| 2020-11-05 | Iniziato | Alliance Global Partners | Buy |
| 2017-12-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-14 | Iniziato | Maxim Group | Buy |
| 2016-08-25 | Iniziato | ROTH Capital | Buy |
| 2016-02-29 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2014-10-01 | Iniziato | MLV & Co | Buy |
| 2014-07-22 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - TradingView
ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
What is HC Wainwright’s Forecast for ATNM FY2027 Earnings? - Defense World
Indo-Asian News Service - IANS India Pvt Ltd
ATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. Investors - TradingView
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit - PR Newswire
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM - TradingView
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - TradingView
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - TradingView
Actinium Pharmaceuticals unveils non-PSMA-targeting Ac-225 radiotherapy for prostate cancer - BioWorld Online
Actinium Pharmaceuticals ($ATNM) Misleading Trial Results and FDA Approval Case - TradingView
Actinium Pharmaceuticals secures Ac-225 supply from Eckert & Ziegler - DOTmed
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) - Business Wire
Breakthrough: New Prostate Cancer Treatment Achieves Near-Complete Tumor Elimination in Preclinical Study - StockTitan
Actinium Pharmaceuticals unveils novel prostate cancer therapy - Investing.com
Game-Changing Cancer Treatment: Actinium's New Non-PSMA Therapy Targets $50B+ Market - StockTitan
Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago - Endpoints News
Actinium rises ahead of presentation at Trump Mar-a-Lago Club - MSN
Actinium stock rises ahead of Mar-a-Lago event (ATNM:NYSE) - Seeking Alpha
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire
Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event - Stocks Telegraph
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - StockTitan
Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities - Marketscreener.com
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - PR Newswire
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateATNM - ACCESS Newswire
Major Cancer Breakthrough: Actinium and MSK Join Forces to Transform AML Treatment Landscape - StockTitan
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy - PR Newswire
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Cl - Longview News-Journal
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Yahoo Finance
Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy - Marketscreener.com
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO - Longview News-Journal
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - Longview News-Journal
Game-Changing Leukemia Treatment Extends Survival 6x Longer Than Standard Therapy - StockTitan
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts - Defense World
HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Citizentribune
Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan
Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI - Marketscreener.com
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire
Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients - StockTitan
Actinium Pharmaceuticals stock hits 52-week low at $1.07 By Investing.com - Investing.com Canada
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
Actinium Pharmaceuticals Inc Azioni (ATNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):